-SCiSTAR Investigator and Patient Will Join Call to Discuss Experiences with AST-OPC1-
FREMONT, Calif., Nov. 4, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release third quarter financial results and provide an update on clinical progress on Monday, November 14, 2016 after the close of the U.S. financial markets.
The Company will host a conference call and webcast on November 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Company management will be joined by Shekar N. Kurpad, MD, PhD, Professor of Neurosurgery, Director, Spinal Cord Injury Center Medical College of Wisconsin and a clinical investigator for the SCiStar study. Dr. Kurpad will discuss his experience to date with AST-OPC1 at his institution, and will be joined on the call by one of his patients who received AST-OPC1. To access a video that includes Dr. Kurpad, other clinical investigators, as well as patients who have been treated with AST-OPC1, please click on the following link: http://asteriasbiotherapeutics.com/.
For both "listen-only" participants and those participants who wish to take part in the question-and-answer session, the call can be accessed by dialing 877-719-9799 (U.S./Canada) or 719-325-4838 (international) five minutes prior to the start of the call and providing the Conference ID 5481738. To access the live webcast, go to http://asteriasbiotherapeutics.com/events-presentations/.
A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by dialing 888-203-1112 (U.S./Canada) or 719-457-0820 (international) and providing the Conference ID 5481738. Additionally, the archived webcast will be available at http://asteriasbiotherapeutics.com/events-presentations/.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.
AST-VAC1 (antigen-presenting autologous dendritic cells) is undergoing continuing development by Asterias after demonstrating promise in a Phase 2 study in Acute Myeloid Leukemia (AML) and completing a successful end-of-Phase 2 meeting with the FDA. The company is currently focused on streamlining and modernizing the manufacturing process for AST-VAC1 in advance of a planned initiation of a confirmatory phase 2b study in 2018. AST-VAC2 (antigen-presenting allogeneic dendritic cells) represents a second generation, allogeneic immunotherapy. The company's research partner, Cancer Research UK, plans to begin a Phase 1/2a clinical trial of AST-VAC2 in non-small cell lung cancer in the first half of 2017. Additional information about Asterias can be found at www.asteriasbiotherapeutics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asterias-biotherapeutics-to-report-third-quarter-results-on-november-14-2016-300357466.html
SOURCE Asterias Biotherapeutics, Inc.